Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis - Wikidata - wikimedia - TriplyDB

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

http://www.wikidata.org/entity/Q26863404

about

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis Application of new acute kidney injury biomarkers in human randomized controlled trials.Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.Biomarkers of Renal Function: Towards Clinical Actionability.Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial.Urine Trefoil Factors as Prognostic Biomarkers in Chronic Kidney Disease.

P2860

Q36127484-52461467-DA21-410A-A162-510545E17413 Q36909005-03DF2BF0-D23A-4A1C-AABD-2C9AACBC5C04 Q37114337-4D4C9964-B087-40FD-9F4B-42580A95ACC9 Q38545232-F7677ED7-0404-4D2C-A772-09AAB6536F29 Q39368726-C66B75D8-9D93-499E-8845-FD55D37B099D Q40436912-7B8134E2-E8AC-4262-AFB3-BC31B4E6218C Q42722902-89561079-28A6-46B2-BD49-639AA0092BD9 Q47141872-236EDA74-13A6-4795-92A9-24BD2C282AEE Q47735571-6934EE15-A520-408D-81AF-ABE2FA4A1521 Q55406066-84919701-889F-416E-A028-0B3C0DDA9C3D

P2860

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

http://www.wikidata.org/entity/Q26863404

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@ast

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@en

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@nl

type

label

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@ast

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@en

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@nl

prefLabel

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@ast

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@en

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@nl

P1433

Q26863404-AE8B67E3-D93E-46AB-83BC-E60238B4AF3A

P1476

Q26863404-56F44CBA-8C2F-444A-A802-ACA5BD20DBF0

P2093

Q26863404-133CCCFC-B0E5-4BFF-A8CA-F80A311A2CC3

Q26863404-B4E8B662-19C9-439F-99FC-5C796F4480C5

Q26863404-C806C46A-6B39-4BBA-967E-76F9BF758EC5

Q26863404-D59B3812-4394-4E67-A80B-49B6AB28580E

Q26863404-FB8DFEF5-87B8-4091-8F3D-6E2650F88BCB

P2860

Q26863404-019ECEE6-B38A-44CC-B3B1-4B2B117F572D

Q26863404-0C2A20CB-4DCA-45A8-93B4-7846D051256B

Q26863404-101AA626-137B-42F2-A99E-E2A22B75B407

Q26863404-14F53ADE-2C1E-4B2F-9F36-103394A22D83

Q26863404-18DB44B2-DAA5-42A2-A014-3617C54BBD03

Q26863404-2156114E-5D18-4E7F-B0B2-9EFF028C7127

Q26863404-26F1B405-8FA3-493C-B7E3-89761FAB59A9

Q26863404-2F39529E-61A8-4885-B103-40F9377D6FFC

Q26863404-30377120-2D87-4093-AC76-3A56735D3F2B

Q26863404-398405B5-1F75-4302-9CC1-2B4BC166BF38

P304

Q26863404-5938C8CC-44C0-469A-8154-90B5E1B38CD1

P31

Q26863404-45A20DB5-DB06-40B8-9461-A787BDD3FDB7

Q26863404-65609B1F-2395-4AB1-ACD2-1FC567F1B19D

P3181

Q26863404-9E2D622C-BD4C-411B-BD04-817A595DFBB1

P356

Q26863404-25764557-51D3-4477-BE26-E9E2DC2B323A

P407

Q26863404-A5696D84-0F86-4A6D-93FC-5A59A6AB9F59

P433

Q26863404-799E60B5-AFC2-4765-B510-9FEA56A1DE96

P478

Q26863404-75C20191-6578-4E87-BA50-9A5461D7F6EC

P50

Q26863404-64898243-61AB-4F99-BD18-D2BA60A457B5

Q26863404-A0FFE80F-1F0B-4285-A9E9-40AE9894A3C4

Q26863404-C0BB5340-5D2B-4AB6-B7A9-26EF1F045A98

P577

Q26863404-BDD39CDF-CB06-4471-986E-2295E0541255

P698

Q26863404-32526322-BA12-417A-B349-EBC1597DB7BB

P932

Q26863404-AC71259B-135E-4010-94E4-AACC2AA064D9

P3181

P356

P1433

Journal of the American Society of Nephrology

P1476

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

@en

P2093

Braden J Manns

http://www.w3.org/2001/XMLSchema#string

Brenda R Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

Hiddo J Lambers Heerspink

http://www.w3.org/2001/XMLSchema#string

Mark Woodward

http://www.w3.org/2001/XMLSchema#string

Vlado Perkovic

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in meta-analysis detected by a simple, graphical test

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Glucose control and vascular complications in veterans with type 2 diabetes

The relationship between proteinuria and coronary risk: a systematic review and meta-analysis

Nephrotoxicity of increased glomerular protein traffic.

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

P304

2289-2302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3620284

http://www.w3.org/2001/XMLSchema#string

P356

10.1681/ASN.2014040396

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Marcello Tonelli

Tanvir C. Turin

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25556165

http://www.w3.org/2001/XMLSchema#string

P932

4552106

http://www.w3.org/2001/XMLSchema#string